{"id":1367,"date":"2026-04-03T15:00:00","date_gmt":"2026-04-03T15:00:00","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=1367"},"modified":"2026-09-07T18:50:29","modified_gmt":"2026-09-07T18:50:29","slug":"selank-peptide-anxiolytic-bdnf-research-guide","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/","title":{"rendered":"Selank Peptide: Anxiolytic Research, BDNF Modulation &#038; Nootropic Applications"},"content":{"rendered":"<p><em>For laboratory and research use only. Not for human consumption.<\/em><\/p>\n<p>Selank started as an immunology project. The goal was better metabolic stability. What they got was a heptapeptide that crosses into neuroscience territory in ways nobody predicted.<\/p>\n<p>Anxiolytic effects comparable to benzodiazepines. No sedation. No amnesia. No dependence. Plus BDNF modulation, enkephalinase inhibition, and immunomodulatory activity all wrapped into seven amino acids. <a href=\"https:\/\/lotilabs.com\/product\/selank-10mg\/\">Selank<\/a> (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is one of those compounds where the mechanism of action section reads like it\u2019s describing four different drugs. But it\u2019s one peptide. And the preclinical data is surprisingly consistent.<\/p>\n<div class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\" id=\"ez-toc-container\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a aria-label=\"Toggle Table of Content\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" href=\"#\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg class=\"list-377408\" fill=\"none\" height=\"20px\" style=\"fill: #999;color:#999\" viewbox=\"0 0 24 24\" width=\"20px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg baseprofile=\"tiny\" class=\"arrow-unsorted-368013\" height=\"10px\" style=\"fill: #999;color:#999\" version=\"1.2\" viewbox=\"0 0 24 24\" width=\"10px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"><\/path><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class=\"ez-toc-list ez-toc-list-level-1\"><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#What_Is_Selank_Chemical_Identity\">What Is Selank? Chemical Identity<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#Development_History\">Development History<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#Mechanism_of_Action_Five_Pathways_From_One_Peptide\">Mechanism of Action: Five Pathways From One Peptide<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#Preclinical_Results\">Preclinical Results<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#Safety_Profile\">Safety Profile<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#Regulatory_Status\">Regulatory Status<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#Availability\">Availability<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#Conclusion\">Conclusion<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#References\">References<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Selank_Chemical_Identity\"><\/span><span class=\"ez-toc-section\" id=\"What_Is_Selank_Chemical_Identity\"><\/span>What Is Selank? Chemical Identity<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Seven amino acids. TKPRPGP. A synthetic regulatory peptide from the tuftsin family.<\/p>\n<ul>\n<li><strong>Sequence:<\/strong> Thr-Lys-Pro-Arg-Pro-Gly-Pro<\/li>\n<li><strong>Molecular Formula:<\/strong> C<sub>33<\/sub>H<sub>57<\/sub>N<sub>11<\/sub>O<sub>9<\/sub><\/li>\n<li><strong>Molecular Weight:<\/strong> 751.87 g\/mol<\/li>\n<li><strong>CAS Number:<\/strong> 129954-34-3<\/li>\n<li><strong>Classification:<\/strong> Synthetic heptapeptide, tuftsin analogue<\/li>\n<li><strong>Solubility:<\/strong> Freely water-soluble<\/li>\n<\/ul>\n<p>The first four residues (Thr-Lys-Pro-Arg) are tuftsin \u2014 a tetrapeptide that the spleen cleaves from IgG\u2019s Fc region. Adding Pro-Gly-Pro onto the C-terminus did two things. It slowed enzymatic degradation \u2014 extending the compound\u2019s active window well beyond what native tuftsin achieves \u2014 and it introduced neurotropic properties that the parent peptide simply doesn\u2019t have.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Development_History\"><\/span><span class=\"ez-toc-section\" id=\"Development_History\"><\/span>Development History<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Late 1990s, early 2000s. Nikolai Myasoedov\u2019s lab at the Institute of Molecular Genetics, Russian Academy of Sciences. The idea: make a tuftsin analogue that\u2019s harder for enzymes to chew apart, keep the immunomodulatory profile, and see what else happens.<\/p>\n<p>What else happened was anxiolytic activity. That makes Selank one of a handful of peptides anywhere in the world with actual regulatory approval as an anxiolytic agent \u2014 though it\u2019s still unapproved by the FDA and EMA, and classified as a research compound in most countries.<\/p>\n<p>Both inhibit enkephalin-degrading enzymes. Different core structures, overlapping but distinct downstream effects.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_Five_Pathways_From_One_Peptide\"><\/span><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_Five_Pathways_From_One_Peptide\"><\/span>Mechanism of Action: Five Pathways From One Peptide<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This is where Selank gets unusual. Most anxiolytics work through one receptor system. Selank hits at least five distinct molecular pathways. That\u2019s not hand-waving \u2014 each one has published data behind it.<\/p>\n<h3>1. GABA<sub>A<\/sub> Receptor Modulation (Without the Benzo Baggage)<\/h3>\n<p>Volkova\u2019s group showed that Selank alters GABA binding at its receptors without competing for the agonist site. Allosteric modulation \u2014 changing how the receptor responds to GABA rather than mimicking GABA directly. That\u2019s the same general category as benzodiazepines, but the details matter enormously.<\/p>\n<p>Kasian et al. (PMID: 26847159) went deeper with a transcriptomic study \u2014 84 genes related to neurotransmission, comparing Selank vs. GABA administration. Strong positive correlation in gene expression changes. Selank isn\u2019t just tweaking receptor binding; it\u2019s shifting the entire GABAergic transcription program.<\/p>\n<p>And yet \u2014 no sedation. No amnesia. No muscle relaxation. No dependence. That separation of anxiolysis from sedation is rare. And pharmacologically interesting.<\/p>\n<h3>2. BDNF and NGF: Neurotrophin Regulation<\/h3>\n<p>This might be Selank\u2019s most important mechanism for neuroscience researchers. The protein curve is more complex: a transient dip followed by a sustained rise above baseline. Rapid signaling cascade first, then slower genomic effects that build over time.<\/p>\n<p>Even more interesting: Kolik et al. (PMID: 31625062) showed that Selank doesn\u2019t just raise BDNF blindly. State-dependent modulation. The compound normalizes BDNF toward physiological levels rather than simply cranking it up \u2014 and that distinction matters for anyone studying the neurotrophin hypothesis of affective disorders.<\/p>\n<p>For researchers working with <a href=\"https:\/\/lotilabs.com\/resources\/delta-sleep-inducing-peptide-dsip-benefits-uses-and-dosage\/\">other regulatory neuropeptides like DSIP<\/a>, Selank\u2019s neurotrophin-centric mechanism opens complementary research angles.<\/p>\n<h3>3. Enkephalinase Inhibition<\/h3>\n<p>Zozulya et al. measured this directly. Selank inhibits the enzymes that break down enkephalins in plasma \u2014 and it does so more potently than bacitracin and puromycin, two established peptidase inhibitors. Since enkephalins get torn apart by aminopeptidases, NEP, and ACE within seconds of release, even modest inhibition of those enzymes meaningfully extends how long enkephalins survive to interact with opioid receptors.<\/p>\n<p>But Selank itself doesn\u2019t bind opioid receptors. Meshavkin et al. confirmed this: naloxone blocks Selank\u2019s behavioral effects (indicating opioid system involvement), yet the peptide shows zero competition at \u03b4 or \u03bc receptor binding sites. Indirect engagement. That\u2019s a subtle but critical pharmacological distinction.<\/p>\n<h3>4. Serotonin and Dopamine<\/h3>\n<p>Nadorova et al. found Selank\u2019s serotonergic effects are state-dependent. Normal baseline conditions? Not much change in 5-HT or 5-HIAA. But when serotonin is pathologically elevated? Selank normalizes accumulation in frontal cortex, hypothalamus, and amygdala. It\u2019s a modulator, not a simple up- or down-regulator.<\/p>\n<p>On the dopamine side, that same Kasian transcriptomic study (PMID: 26847159) caught something specific: Selank activates <em>Drd5<\/em> gene expression \u2014 dopamine receptor D5. Molecular basis for the nootropic effects that behavioral testing has been documenting.<\/p>\n<h3>5. Immunomodulation (The Tuftsin Legacy)<\/h3>\n<p>Selank didn\u2019t forget where it came from.<\/p>\n<p>That neuroimmune crossover is what makes Selank unique among anxiolytic research compounds. Most anxiety drugs don\u2019t touch the immune system.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Preclinical_Results\"><\/span><span class=\"ez-toc-section\" id=\"Preclinical_Results\"><\/span>Preclinical Results<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Kozlovskaya et al. (2003): 300 \u03bcg\/kg in rats. %. Vertical activity up 10.2%. Hole investigations up 23.0%. Selank does the opposite.<\/p>\n<p>Semenova et al. Not just one paradigm. Broad-spectrum anxiolysis.<\/p>\n<h3>Cognition<\/h3>\n<p>Simultaneous anxiolytic and nootropic effects \u2014 both driven, apparently, by BDNF modulation and D5 receptor activation.<\/p>\n<h3>Versus Benzodiazepines<\/h3>\n<p>The head-to-head data against medazepam tells the story clearly:<\/p>\n<ul>\n\n<li>Sedation: absent with Selank (may relate to its upregulation of hypocretin\/Hcrt gene expression \u2014 a wakefulness signal)<\/li>\n<li>Amnesia: absent.<\/li>\n<li>Dependence and withdrawal: none observed in any preclinical model<\/li>\n<\/ul>\n<p>For investigators studying <a href=\"https:\/\/lotilabs.com\/resources\/the-benefits-of-pinealon-peptide-for-brain-and-longevity-research\/\">CNS-active regulatory peptides<\/a>, that\u2019s about as clean a comparison as you\u2019ll find.<\/p>\n<h3>Alcohol Withdrawal<\/h3>\n<p>Chronic ethanol exposure followed by abrupt cessation. Consistent with the compound\u2019s known effects on enkephalin preservation, BDNF normalization, and GABAergic tone. Multiple mechanisms converging on the same withdrawal phenotype.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Safety_Profile\"><\/span><span class=\"ez-toc-section\" id=\"Safety_Profile\"><\/span>Safety Profile<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>What the preclinical and domestic data show:<\/p>\n<ul>\n\n<li><strong>No dependence.<\/strong> No withdrawal. Not even a hint in animal models<\/li>\n<li><strong>No antibody formation<\/strong> \u2014 immunogenicity testing came back clean<\/li>\n<li><strong>Fast clearance:<\/strong> metabolized in the liver, excreted renally. Gone from circulation in about 10 minutes. Low accumulation risk<\/li>\n<\/ul>\n<p>Important caveat: most published safety data comes from Russian research institutions. Independent international replication is limited. Researchers should weigh that when designing protocols and interpreting findings.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Regulatory_Status\"><\/span><span class=\"ez-toc-section\" id=\"Regulatory_Status\"><\/span>Regulatory Status<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Russia:<\/strong> Approved. One of the few peptide anxiolytics with any regulatory approval worldwide.<\/p>\n<p><strong>United States:<\/strong> Not FDA-approved. Research compound only. Not available for compounding under current guidance.<\/p>\n<p><strong>EU\/International:<\/strong> Not EMA-approved. Generally classified as a research compound.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Availability\"><\/span><span class=\"ez-toc-section\" id=\"Availability\"><\/span>Availability<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Loti Labs carries <a href=\"https:\/\/lotilabs.com\/product\/selank-10mg\/\">Selank 10mg<\/a> ($49.99) \u2014 lyophilized, \u226598% purity, third-party HPLC and mass spec verified.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A tuftsin analogue that became an anxiolytic. BDNF regulation that normalizes rather than just elevates. Enkephalinase inhibition that preserves endogenous opioid signaling without touching opioid receptors directly. Serotonin and dopamine modulation. Immunomodulatory activity.<\/p>\n<p>Five pathways from seven amino acids.<\/p>\n<p><em>For laboratory and research use only. Not for human consumption.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"References\"><\/span>References<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ol>\n<li>Kasian A, Kolomin T, Andreeva L, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. <em>Front Pharmacol.<\/em> 2017;8:782. PMID: 26847159<\/li>\n<li>Kolik LG, Nadorova AV, Antipova TA, et al. <em>Bull Exp Biol Med.<\/em> 2019;167(5):641-644. PMID: 31625062<\/li>\n<li>Zozulya AA, Kost NV, Sokolov OY, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. <em>Bull Exp Biol Med.<\/em> 2001;131(4):315-317.<\/li>\n<li>Meshavkin VK, Kost NV, Sokolov OY, et al. Selank action on opioid system is mediated by enkephalinase inhibition. <em>Bull Exp Biol Med.<\/em> 2006;142(5):575-577.<\/li>\n<li>Seredenin SB, Kozlovskaya MM, Blednov YA, et al. <em>Zh Vyssh Nerv Deiat Im I P Pavlova.<\/em> 1998;48(1):153-160.<\/li>\n<li>Kozlovskaya MM, Kozlovskii II, Val\u2019dman EA, Seredenin SB. <em>Neurosci Behav Physiol.<\/em> 2003;33(9):853-860.<\/li>\n<li>Seredenin SB, Blednov YA, Badyshtov BA, et al. <em>Zh Nevrol Psikhiatr Im S S Korsakova.<\/em> 2008;108(4):38-48. PMID: 18454096<\/li>\n<li>Uchakina ON, Uchakin PN, et al. <em>Zh Nevrol Psikhiatr Im S S Korsakova.<\/em> 2008;108(5):71-75.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Research guide on Selank, a synthetic heptapeptide with anxiolytic effects comparable to benzodiazepines without sedation. Covers BDNF modulation, enkephalinase inhibition, and immunomodulatory mechanisms.<\/p>\n","protected":false},"author":1,"featured_media":1384,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-1367","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptides"],"_links":{"self":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/comments?post=1367"}],"version-history":[{"count":0,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1367\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media\/1384"}],"wp:attachment":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media?parent=1367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/categories?post=1367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/tags?post=1367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}